Evidence map›Paper›PMID 30644454›Full record

ArticleNature reviews. Gastroenterology & hepatology2019

Precision dietary supplementation based on personal gut microbiota.

Yu-Jui Yvonne Wan, Prasant Kumar Jena

Abstract readComment
In one paragraph

Article in Nature reviews. Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention?Cellular and molecular gastroenterology and hepatology · 2019
    Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Yu-Jui Yvonne WanDepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA. yjywan@ucdavis.edu.
Prasant Kumar JenaDepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA.

Funding

The Role of Probiotic Bifidobacteria and Bile Acid Metabolism in CarcinogenesisU01CA179582 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLS, DAVID ANDREW, SLUPSKY, CAROLYN · 2014 to 2018
$2.8M
Liver Cancer Therapy by MiR-22 and Its InducersR01CA222490 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WAN, YU-JUI YVONNE · 2018 to 2023
$2.1M
NCI NIH HHS R01 CA222490NCI NIH HHS U01 CA179582
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gastrointestinal MicrobiomeLiver NeoplasmsMicrobiotaAdultDietary SupplementsFermentationHumans

Identifiers

PMID30644454
PMCPMC7182348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.